Provenance Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Provenance Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.97K	Buy	+10	New	+$4.43K	﹤0.01%	383

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Provenance Wealth Advisors's VRTX Position: Q2 2026 in Review

Provenance Wealth Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 10 shares worth $4.97K. The stake represents ﹤0.01% of the portfolio and ranks #383 among its holdings.

1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Provenance Wealth Advisors held 10 shares of Vertex Pharmaceuticals worth $4.97K as of Q2 2026.
Vertex Pharmaceuticals was a new Provenance Wealth Advisors position in Q2 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Provenance Wealth Advisors's portfolio in Q2 2026, its #383 holding.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Provenance Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.